Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989583 | 0.85 | METAP1 (0.56) | BRD4MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30468628 | 0.80 | HTT (0.51) | BRD4MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1989692 | 0.80 | HTT (0.51) | BRD4MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2419938 | 0.78 | KDM4E (0.49) | BRD4CETPMAPTCYP1A2CYP3A4 | |
| SCHEMBL15491378 | 0.78 | SMN1; SMN2 (0.39) | BRD4CETPMAPTCYP1A2CYP2C19 | |
| SCHEMBL457581 | 0.76 | MAPT (0.54) | BRD4MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4255346 | 0.74 | TSHR (0.45) | CETPMAPTCYP3A4CYP2C19KDM4E | |
| SCHEMBL4254113 | 0.74 | TSHR (0.43) | CETPMAPTCYP3A4CYP2C19KDM4E | |
| SCHEMBL31547757 | 0.74 | TSHR (0.45) | CETPMAPTCYP3A4CYP2C19KDM4E | |
| SCHEMBL20659270 | 0.74 | BRD4 (0.47) | BRD4MAPTCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1709045-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050171141-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-04 | — | — | US | disclosed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171141-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | BRD4 832/4885CETP 2290/4885MAPT 2360/4885 |
| US-20090042928-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | BRD4 832/4885CETP 2290/4885MAPT 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.